Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DRRX Stock Forecast 2026-2027
$1.91
Current Price
$59.31M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to DRRX Price Targets
+30.9%
To High Target of $2.50
+30.9%
To Median Target of $2.50
+30.9%
To Low Target of $2.50
DRRX Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+154.7%
1 Year Change
0.0%
Year-to-Date Change
-27.7%
From 52W High of $2.64
+297.9%
From 52W Low of $0.48
📊 TOP ANALYST CALLS
Did DRRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Durect is one of their latest high-conviction picks.
Latest DRRX Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, DRRX has a neutral consensus with a median price target of $2.50 (ranging from $2.50 to $2.50). The overall analyst rating is N/A (N/A/10). Currently trading at $1.91, the median forecast implies a 30.9% upside. This outlook is supported by 0 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DRRX Analyst Ratings
0
Buy
1
Hold
0
Sell
DRRX Price Target Range
Low
$2.50
Average
$2.50
High
$2.50
Current: $1.91
Latest DRRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DRRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 27, 2025 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $N/A |
| Nov 14, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $N/A |
| Sep 26, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $N/A |
| May 22, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $N/A |
| May 15, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $N/A |
| Apr 1, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $5.00 |
| Mar 28, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $N/A |
| Nov 9, 2023 | JonesTrading | Sean Kim | Hold | Downgrade | $N/A |
| Nov 8, 2023 | HC Wainwright & Co. | Ed Arce | Neutral | Downgrade | $N/A |
| Nov 7, 2023 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| Aug 10, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $27.00 |
| Aug 10, 2023 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $41.00 |
| May 17, 2023 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $44.00 |
| May 9, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| Apr 11, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| Mar 14, 2023 | JonesTrading | Sean Kim | Buy | Initiates | $37.00 |
| Mar 8, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $32.00 |
| Dec 7, 2022 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $32.00 |
| May 5, 2021 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Feb 3, 2021 | Chardan Capital | Michael Morabito | Buy | Maintains | $8.00 |
Durect Corporation (DRRX) Competitors
The following stocks are similar to Durect based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Durect Corporation (DRRX) Financial Data
Durect Corporation has a market capitalization of $59.31M with a P/E ratio of -7.6x. The company generates $1.66M in trailing twelve-month revenue with a -209.9% profit margin.
Revenue growth is -30.8% quarter-over-quarter, while maintaining an operating margin of -627.1% and return on equity of -307.4%.
Valuation Metrics
Market Cap
$59.31M
Enterprise Value
$54.56M
P/E Ratio
-7.6x
PEG Ratio
0.2x
Price/Sales
35.8x
Growth & Margins
Revenue Growth (YoY)
-30.8%
Gross Margin
+98.4%
Operating Margin
-627.1%
Net Margin
-209.9%
EPS Growth
-79.4%
Financial Health
Cash/Price Ratio
+10.9%
Current Ratio
1.0x
Debt/Equity
50.2x
ROE
-307.4%
ROA
-45.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Durect Corporation (DRRX) Business Model
About Durect Corporation
What They Do
Biopharmaceutical company developing innovative drug solutions.
Business Model
Durect Corporation generates revenue by developing and commercializing pharmaceutical products, particularly focusing on pain management and chronic diseases. The company employs extended-release drug delivery technologies and collaborates with other pharmaceutical firms to enhance drug development and distribution, which allows it to leverage synergies and expand its market reach.
Additional Information
Founded in 1998 and headquartered in Cupertino, California, Durect is dedicated to improving therapeutic outcomes and reducing healthcare costs. Its notable investigational products, such as a post-surgical pain management system, aim to improve patient recovery and quality of life, positioning the company as a significant player in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
13
CEO
Dr. James E. Brown D.V.M.
Country
United States
IPO Year
2000
Website
www.durect.comDurect Corporation (DRRX) Latest News & Analysis
Latest News
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025
7 months ago
Quick Summary
Bausch Health has extended its tender offer to acquire DURECT Corporation at $1.75 per share, totaling about $63 million, with potential milestone payments of up to $350 million.
Why It Matters
Bausch Health's acquisition of DURECT could enhance its product portfolio and revenue potential, impacting stock performance and investor sentiment based on growth prospects.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bausch Health will acquire DURECT Corporation for $1.75 per share and up to $350 million in sales milestones, with the transaction expected to close in Q3 2025.
Why It Matters
Bausch Health's acquisition of DURECT Corp. could affect stock prices and market positioning, impacting investor sentiment and future growth potential for both companies.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Durect (DRRX) reported a quarterly loss of $0.07 per share, better than the expected loss of $0.13, and an improvement from a loss of $0.12 per share a year earlier.
Why It Matters
Durect's smaller-than-expected loss signals potential operational improvement, which may boost investor confidence and affect stock performance positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of DURECT Corporation (NASDAQ: DRRX)
8 months ago
Quick Summary
Monteverde & Associates is investigating DURECT Corporation's sale to Bausch Health for $1.75 per share, raising questions about the fairness of the deal for shareholders.
Why It Matters
The investigation into DURECT's sale price raises concerns about shareholder value, potentially affecting stock performance and investor sentiment toward the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The Ademi Firm is investigating DURECT (NYSE: DRRX) for potential fiduciary duty violations related to its deal with Bausch Health, offering shareholders $1.75 per share in cash.
Why It Matters
The investigation into DURECT for potential fiduciary breaches may indicate legal risks, potentially affecting share value and investor confidence amid the cash transaction with Bausch Health.
Source: Business Wire
Market Sentiment:
Neutral
DRRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DURECT Corporation Is Fair to Shareholders
8 months ago
Quick Summary
Halper Sadeh LLC is investigating the fairness of DURECT Corporation's sale to Bausch Health for $1.75 per share, encouraging shareholders to explore their legal rights.
Why It Matters
The investigation into DURECT's sale price may indicate potential undervaluation, raising concerns about shareholder rights and the fairness of the acquisition, impacting investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About DRRX Stock
What is Durect Corporation's (DRRX) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Durect Corporation (DRRX) has a median price target of $2.50. The highest price target is $2.50 and the lowest is $2.50.
Is DRRX stock a good investment in 2026?
According to current analyst ratings, DRRX has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.91. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DRRX stock?
Wall Street analysts predict DRRX stock could reach $2.50 in the next 12 months. This represents a 30.9% increase from the current price of $1.91. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Durect Corporation's business model?
Durect Corporation generates revenue by developing and commercializing pharmaceutical products, particularly focusing on pain management and chronic diseases. The company employs extended-release drug delivery technologies and collaborates with other pharmaceutical firms to enhance drug development and distribution, which allows it to leverage synergies and expand its market reach.
What is the highest forecasted price for DRRX Durect Corporation?
The highest price target for DRRX is $2.50 from at , which represents a 30.9% increase from the current price of $1.91.
What is the lowest forecasted price for DRRX Durect Corporation?
The lowest price target for DRRX is $2.50 from at , which represents a 30.9% increase from the current price of $1.91.
What is the overall DRRX consensus from analysts for Durect Corporation?
The overall analyst consensus for DRRX is neutral. Out of 6 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $2.50.
How accurate are DRRX stock price projections?
Stock price projections, including those for Durect Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 16, 2026 4:39 AM UTC